Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.

Despite their initial efficient response to induction chemotherapy, relapse remains frequent in patients with T-cell acute lymphoblastic leukemia (T-ALL), an aggressive malignancy of immature T ...

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

Researchers at the University of Illinois Chicago have redesigned the enzyme asparaginase for the treatment of acute lymphoblastic ... The compound destroyed leukemia cells in mice and shrank ...

Chronic lymphocytic leukemia ... a high white blood cell or lymphocyte level. You’d get more tests to find out if this is leukemia. Two other types of leukemia -- acute myeloid leukemia ...

for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Approval was based on results from the ...

The FDA approved obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute ...

CD37, a surface protein present on most acute myeloid leukemia (AML ... with normal hematopoietic stem cells, peripheral blood mononuclear cells, and AML cell lines. Analysis included ...

The CAR T-cells then recognise and attack the cancer cells. Some children and young people up the age of 25 years have a type of CAR T-cell therapy called tisagenlecleucel (Kymriah). It is for a type ...

Marlise R. Luskin, MD, MSCE, speaks with Healio about findings from the phase 3 randomized Alliance A041501 trial.The study was put on hold due to grade 5 events among patients who received inotuzumab ...

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...